» Articles » PMID: 38238519

The Expanding Diagnostic Toolbox for Rare Genetic Diseases

Overview
Journal Nat Rev Genet
Specialty Genetics
Date 2024 Jan 18
PMID 38238519
Authors
Affiliations
Soon will be listed here.
Abstract

Genomic technologies, such as targeted, exome and short-read genome sequencing approaches, have revolutionized the care of patients with rare genetic diseases. However, more than half of patients remain without a diagnosis. Emerging approaches from research-based settings such as long-read genome sequencing and optical genome mapping hold promise for improving the identification of disease-causal genetic variants. In addition, new omic technologies that measure the transcriptome, epigenome, proteome or metabolome are showing great potential for variant interpretation. As genetic testing options rapidly expand, the clinical community needs to be mindful of their individual strengths and limitations, as well as remaining challenges, to select the appropriate diagnostic test, correctly interpret results and drive innovation to address insufficiencies. If used effectively - through truly integrative multi-omics approaches and data sharing - the resulting large quantities of data from these established and emerging technologies will greatly improve the interpretative power of genetic and genomic diagnostics for rare diseases.

Citing Articles

International Precision Child Health Partnership (IPCHiP): an initiative to accelerate discovery and improve outcomes in rare pediatric disease.

Howell K, White S, McTague A, DGama A, Costain G, Poduri A NPJ Genom Med. 2025; 10(1):13.

PMID: 40016282 PMC: 11868529. DOI: 10.1038/s41525-025-00474-8.


Researcher views on returning results from multi-omics data to research participants: insights from The Molecular Transducers of Physical Activity Consortium (MoTrPAC) Study.

Ormond K, Stanclift C, Reuter C, Carter J, Murphy K, Lindholm M BMC Med Ethics. 2025; 26(1):22.

PMID: 39920727 PMC: 11804059. DOI: 10.1186/s12910-025-01174-9.


Drosophila modeling to identify causative genes and reveal the underlying molecular mechanisms for primary ovarian insufficiency.

Ma Y, Liu Y, Xu M, Yin X, Hu C, Yang X J Mol Med (Berl). 2025; 103(2):239-253.

PMID: 39853375 DOI: 10.1007/s00109-025-02516-1.


Recent Advances in the Genetics of Ataxias: An Update on Novel Autosomal Dominant Repeat Expansions.

Pellerin D, Iruzubieta P, Xu I, Danzi M, Cortese A, Synofzik M Curr Neurol Neurosci Rep. 2025; 25(1):16.

PMID: 39820740 DOI: 10.1007/s11910-024-01400-8.


Expanding Upon Genomics in Rare Diseases: Epigenomic Insights.

Tan J, Blake E, Farris J, Klee E Int J Mol Sci. 2025; 26(1.

PMID: 39795993 PMC: 11719497. DOI: 10.3390/ijms26010135.


References
1.
Ferreira C . The burden of rare diseases. Am J Med Genet A. 2019; 179(6):885-892. DOI: 10.1002/ajmg.a.61124. View

2.
Wakap S, Lambert D, Olry A, Rodwell C, Gueydan C, Lanneau V . Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2019; 28(2):165-173. PMC: 6974615. DOI: 10.1038/s41431-019-0508-0. View

3.
Costa T, Scriver C, Childs B . The effect of Mendelian disease on human health: a measurement. Am J Med Genet. 1985; 21(2):231-42. DOI: 10.1002/ajmg.1320210205. View

4.
Marshall D, Benchimol E, Mackenzie A, Rodriguez Duque D, MacDonald K, Hartley T . Direct health-care costs for children diagnosed with genetic diseases are significantly higher than for children with other chronic diseases. Genet Med. 2018; 21(5):1049-1057. DOI: 10.1038/s41436-018-0289-9. View

5.
Liu Z, Zhu L, Roberts R, Tong W . Toward Clinical Implementation of Next-Generation Sequencing-Based Genetic Testing in Rare Diseases: Where Are We?. Trends Genet. 2019; 35(11):852-867. DOI: 10.1016/j.tig.2019.08.006. View